These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16286897)

  • 1. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.
    Schonland SO; Perz JB; Hundemer M; Hegenbart U; Kristen AV; Hund E; Dengler TJ; Beimler J; Zeier M; Singer R; Linke RP; Ho AD; Goldschmidt H
    Transplantation; 2005 Sep; 80(1 Suppl):S160-3. PubMed ID: 16286897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.
    Schönland SO; Dreger P; de Witte T; Hegenbart U
    Bone Marrow Transplant; 2012 Jul; 47(7):895-905. PubMed ID: 21785469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
    Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
    Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing systemic light-chain amyloidosis.
    Comenzo RL
    J Natl Compr Canc Netw; 2007 Feb; 5(2):179-87. PubMed ID: 17335687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
    Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
    Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
    Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
    Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
    Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
    Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.
    Hoshino J; Ubara Y; Sawa N; Sumida K; Hiramatsu R; Hasegawa E; Suwabe T; Hayami N; Yamanouchi M; Takemoto F; Taniguchi S; Takaichi K
    Clin Exp Nephrol; 2011 Aug; 15(4):486-92. PubMed ID: 21387097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.